who invented glp 1 drugs Lotte Bjerre Knudsen: The Scientist Drove GLP-1 For Obesity and Alzheimer's Discovery of GLP-1–Based Drugs for
Description
In the ATTAIN-1 Phase 3 trial, the most frequently reported adverse events with orforglipron 36 mg versus placebo were nausea (33.7% vs 10.4%), constipation (25.4% vs 9.3%), diarrhea (23.1% vs 9.6%), and vomiting (24.0% vs 4.0%)
Knop, F.K
doi:10.1007/bf02427280 16
2nd & Duva, M
Up to 20% of (specialty) drugs can be cost-saving, that is, for each dollar spent payers can actually save money over a given period of time in terms of lower downstream costs
ET on Nov 22, 2025
